Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.58 |
| ▸ | GOPC | Q9HD26 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3751857 | 0.98 | CFTR (0.56) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5075468 | 0.93 | CFTR (0.63) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18228201 | 0.91 | SLC6A2 (0.50) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18228425 | 0.91 | CFTR (0.50) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10371774 | 0.86 | POLB (0.51) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10561123 | 0.86 | CYP17A1 (0.60) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6730606 | 0.86 | CFTR (0.46) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3832267 | 0.86 | CYP19A1 (0.68) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10562053 | 0.86 | CFTR (0.46) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7404866 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017024015-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017024003-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017023993-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017024025-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | KC SUNIL KUMAR (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2017023981-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| WO-2016040184-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2016-03-17 | — | — | WO | claimed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| WO-2017023981-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| US-8030332-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030332-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20090069312-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| US-20090069312-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| EP-1981508-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089743-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089743-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069312-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | CFTR 479/4885GOPC 989/4885SLC6A2 851/4885 |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | CFTR 1319/4885GOPC 4740/4885SLC6A2 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.